-
Maureen Farrell
Posts
Carl Icahn, Activist Investor, Faces Intense Scrutiny From Wall Street
The 88-year-old activist investor’s stake in his own company has fallen by nearly $20 billion. Mr. Icahn said that he was “absolutely not selling.”
Two Sigma Hedge Fund Replaces John Overdeck and David Siegel as Co-C.E.O.s
The multibillion-dollar trading firm said that its billionaire co-chief executives, John Overdeck and David Siegel, would step down.
Private REITS Were a Hot Investment Trend, but They’ve Lost Some Appeal
Drawn by the opportunity to invest with private equity firms, small investors rushed into real estate investment trusts. But the funds have lost some appeal…
Bill Ackman Abruptly Withdraws Planned I.P.O.
The announcement came a day after he had scaled back the expected size of the offering.
Bill Ackman Scales Back Multibillion-Dollar Fund I.P.O.
An investment fund from William Ackman aims to raise around $2 billion, according to a regulatory filing, a fraction of what was originally envisioned.
Starwood REIT, Facing a Possible Cash Crunch, Limits Withdrawals
Starwood Real Estate Investment Trust is restricting what investors can redeem rather than sell its properties to raise cash.
What’s BlackRock Without Larry Fink? Shareholders Fret About Future.
Investors in the world’s biggest asset manager are asking how much more room it has to grow and who will drive that growth once its…
Famously Obstinate, Bill Ackman Is Now Real-Life Famous. What Next?
The hedge-funder who loves a public crusade — and taking charge — is on to a new stage of his career: online warrior.
A Pre-I.P.O. Gift to Company Executives: ‘11th-Hour Options Discounting’
A new research paper finds that companies price stock options at steep discounts just before going public and take steps to obscure them.
Years After Monsanto Deal, Bayer’s Roundup Bills Keep Piling Up
Juries recently awarded plaintiffs more than $2 billion in damages tied to Roundup, the weedkiller that has been linked to cancer. Bayer is fighting back.